ArticleJournal of addiction medicine2020
Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas.
Article in Journal of addiction medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Patients' and Clinicians' Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study.Journal of general internal medicine · 2024Article
- Leveraging prescription monitoring program data to evaluate the implementation of buprenorphine telehealth flexibilities: An interrupted time series analysis in Texas.Drug and alcohol dependence reports · 2024Article
- Real-World Dispensing of Buprenorphine in California during Prepandemic and Pandemic Periods.Healthcare (Basel, Switzerland) · 2024Article
- Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study.Substance use & misuse · 2023Article
- The Impact of COVID-19 on Opioid-Related Overdose Deaths in Texas.International journal of environmental research and public health · 2022Article
- The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic.Addiction (Abingdon, England) · 2022Article
- Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State.JMIR public health and surveillance · 2022Article
- Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.Drug and alcohol dependence · 2022Article
- Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms.Journal of substance abuse treatment · 2022Article
- The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review.Substance abuse treatment, prevention, and policy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo measure the change in the daily number of patients receiving buprenorphine and buprenorphine prescribers during the early phase of the COVID-19 (SARS-CoV-2) pandemic in Texas.
methodsCounts of the number of patients filling and number of providers prescribing buprenorphine were calculated for each weekday between November 4, 2019 and May 12, 2020. The change in daily patients and prescribers between March 2, 2020 and May 12, 2020, was modeled as a change in slope compared to the baseline period using autoregressive, interrupted time series regression.
resultsThe rate of change of daily buprenorphine prescriptions (β = -1.75, 95% CI = -5.8-2.34) and prescribers (β = -0.32, 95% CI = -1.47-0.82) declined insignificantly during the COVID-19 period compared to the baseline.
conclusionsDespite a 57% decline in ambulatory care utilization in the south-central US during March and April of 2020, health services utilization related to buprenorphine in Texas remained robust. Protecting access to buprenorphine as the COVID-19 pandemic continues to unfold will require intensive efforts from clinicians and policy makers alike. While the presented results are promising, researchers must continue monitoring and exploring the clinical and humanistic impact of COVID-19 on the treatment of substance use disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.